|
- Eli Lilly Cuts Zepbound Price to Widen Access for Obesity Drug
Dec 1 (Reuters) - Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U S patients, as demand for
- Eli Lilly cuts cash prices of Zepbound weight loss drug vials
The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access
- Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials
Lilly continues efforts to expand access for people living with obesity by lowering the price of Zepbound single-dose vials INDIANAPOLIS, Dec 1, 2025 -- Eli Lilly and Company (NYSE: LLY) announced Zepbound ® (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the company’s digital healthcare platform
- Eli Lilly cuts Zepbound prices in competitive weight loss drug market . . .
Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform
- Lilly cuts price for obesity drug Zepbound - USA TODAY
Eli Lilly on Monday, Dec 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker Lilly's price cuts ranged
- Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal
The pharmaceutical giant and Novo Nordisk said they would lower the prices of their popular weight loss drugs to expand access
- Eli Lillys Popular Weight Loss Zepbound Price Goes Down, Now More . . .
Summary Eli Lilly has cut cash prices for its weight-loss drug Zepbound on LillyDirect, lowering monthly costs to $299–$449 The move follows Novo Nordisk’s recent discounts and aligns with new Trump administration deals aimed at improving affordability and access as competition in the booming obesity drug market intensifies Read on to know more
- Eli Lilly cuts Zepbound price to widen access for obesity drug
Bengaluru: Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U S patients, as demand for weight-loss therapies surge Patients with a prescription can now buy the starting dose of 2 5 mg for $299 per month, down from $349, through LillyDirect, the drugmaker's online healthcare platform Price
|
|
|